JP2014205674A5 - - Google Patents

Download PDF

Info

Publication number
JP2014205674A5
JP2014205674A5 JP2014102751A JP2014102751A JP2014205674A5 JP 2014205674 A5 JP2014205674 A5 JP 2014205674A5 JP 2014102751 A JP2014102751 A JP 2014102751A JP 2014102751 A JP2014102751 A JP 2014102751A JP 2014205674 A5 JP2014205674 A5 JP 2014205674A5
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
acid residues
variable domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014102751A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014205674A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014205674A publication Critical patent/JP2014205674A/ja
Publication of JP2014205674A5 publication Critical patent/JP2014205674A5/ja
Pending legal-status Critical Current

Links

JP2014102751A 2008-03-26 2014-05-16 抗vegf抗体 Pending JP2014205674A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3971908P 2008-03-26 2008-03-26
US61/039,719 2008-03-26

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2011501758A Division JP5823858B2 (ja) 2008-03-26 2008-10-08 抗vegf抗体

Publications (2)

Publication Number Publication Date
JP2014205674A JP2014205674A (ja) 2014-10-30
JP2014205674A5 true JP2014205674A5 (enExample) 2015-03-12

Family

ID=41114205

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011501758A Active JP5823858B2 (ja) 2008-03-26 2008-10-08 抗vegf抗体
JP2014102751A Pending JP2014205674A (ja) 2008-03-26 2014-05-16 抗vegf抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2011501758A Active JP5823858B2 (ja) 2008-03-26 2008-10-08 抗vegf抗体

Country Status (9)

Country Link
US (2) US7803371B2 (enExample)
EP (1) EP2259795B1 (enExample)
JP (2) JP5823858B2 (enExample)
KR (1) KR101581244B1 (enExample)
CN (2) CN103992405B (enExample)
AU (1) AU2008353479B2 (enExample)
BR (1) BRPI0822556B1 (enExample)
CA (3) CA2719400C (enExample)
WO (1) WO2009120178A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE032894T2 (hu) * 2008-06-25 2017-11-28 Esbatech Alcon Biomed Res Unit VEGF-gátló, stabilis és oldható antitestek
CN102002104A (zh) * 2009-08-28 2011-04-06 江苏先声药物研究有限公司 一种抗vegf的单克隆抗体及含有该抗体的药物组合物
CA2778084A1 (en) * 2009-10-23 2011-04-28 Garvan Institute Of Medical Research Modified variable domain molecules and methods for producing and using same
AU2012223449A1 (en) * 2011-03-03 2013-05-02 Apexigen, Inc. Anti-IL-6 receptor antibodies and methods of use
CN104650229A (zh) * 2011-11-02 2015-05-27 埃派斯进有限公司 抗-kdr抗体和使用方法
CN103417964A (zh) * 2012-05-17 2013-12-04 江苏先声药物研究有限公司 一种抗vegf抗体的用途
CN103417965B (zh) * 2012-05-17 2018-04-13 江苏先声药业有限公司 一种含有抗vegf抗体的药物组合物
SMT202000088T1 (it) 2013-02-18 2020-03-13 Vegenics Pty Ltd Molecole leganti ligandi e relativi usi
JP2016530244A (ja) * 2013-12-31 2016-09-29 ディベロップメント センター フォー バイオテクノロジーDevelopment Center For Biotechnology 抗vegf抗体及びその使用
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
WO2016115521A1 (en) * 2015-01-16 2016-07-21 Alder Biopharmaceuticals, Inc. Anti-glycoprotein antibodies and uses thereof
TN2017000543A1 (en) * 2015-07-06 2019-04-12 Ucb Biopharma Sprl Tau-binding antibodies
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
BR112018013407A2 (en) 2015-12-30 2018-12-18 Kodiak Sciences Inc. antibodies and conjugates thereof
SG11202008242XA (en) 2018-03-02 2020-09-29 Kodiak Sciences Inc Il-6 antibodies and fusion constructs and conjugates thereof
MX2022002855A (es) * 2019-09-13 2022-06-02 Admare Therapeutics Soc Anticuerpos antiantígenos de virus oncolíticos y métodos de uso de los mismos.
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
CN120769866A (zh) * 2022-12-29 2025-10-10 Ltz治疗股份有限公司 抗CD79b抗体及其用途
CN118344476B (zh) * 2024-05-16 2024-11-15 武汉爱博泰克生物科技有限公司 人c反应蛋白单克隆抗体、抗体对和检测试剂或试剂盒及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2223705T3 (es) * 1999-04-28 2005-03-01 Board Of Regents, The University Of Texas System Composiciones y metodos para el tratamiento de cancer mediante inhibi cion selectiva del vegf.
CN1299833A (zh) * 1999-12-30 2001-06-20 华西医科大学口腔医学研究所 抗人血管内皮生长因子单链抗体及其制备方法
US20040185040A1 (en) * 2001-11-21 2004-09-23 Celltech R & D Limited Modulating immune responses
CA2492524A1 (en) * 2002-08-15 2004-02-26 Epitomics, Inc. Humanized rabbit antibodies
AU2003259718A1 (en) 2003-08-07 2005-03-07 Epitomics, Inc. Methods for humanizing rabbit monoclonal antibodies
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
US7431927B2 (en) * 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
CN104004094B (zh) * 2008-06-25 2017-09-22 艾斯巴技术-诺华有限责任公司 使用通用抗体构架进行的兔抗体的人源化
CN102002104A (zh) * 2009-08-28 2011-04-06 江苏先声药物研究有限公司 一种抗vegf的单克隆抗体及含有该抗体的药物组合物

Similar Documents

Publication Publication Date Title
JP2014205674A5 (enExample)
JP2013198490A5 (enExample)
JP2017176174A5 (enExample)
JP2011517447A5 (enExample)
JP2020500538A5 (enExample)
ES2776179T3 (es) Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
JP2017507652A5 (enExample)
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
AU2016204274A1 (en) Antibodies that bind to OX40 and their uses
JP2013538057A5 (enExample)
JP2017052784A5 (enExample)
JP2014526898A5 (enExample)
JP2012116856A5 (enExample)
NZ629829A (en) Anti-c5a antibodies and methods for using the antibodies
JP2018521638A5 (enExample)
PE20181270A1 (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
MX2018015584A (es) Anticuerpos anti-pd-l1 y usos de los mismos.
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
RU2016100892A (ru) Антитела против tweakr и их применение
JP2017528476A5 (enExample)
JP2015504421A5 (enExample)
HRP20200767T1 (hr) Humanizirana anti-humana cd19 protutijela i postupci uporabe
JP2012010714A5 (enExample)
JP2016507470A5 (enExample)
JP2016530223A5 (enExample)